# Enova International, Inc.: financial statements, quarterly

ENVA · NYSE · CIK 1529864 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/enva.md) · [Financials](/companies/enva/financials.md) · [Filings](/companies/enva/filings.md) · [Insiders](/companies/enva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/enva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [584 d](/filings/0001193125-26-060461.md) | [610](/filings/0000950170-25-060339.md) | [628](/filings/0000950170-25-098791.md) | [690](/filings/0001193125-25-249986.md) | [730 d](/filings/0001193125-26-060461.md) | [746](/filings/0001193125-26-174021.md) | [764](/filings/0001193125-26-314590.md) | [803](/filings/0001193125-26-429122.md) | [839 d](/filings/0001193125-26-060461.md) | [875](/filings/0001193125-26-174021.md) | [929](/filings/0001193125-26-314590.md) | [1,009](/filings/0001193125-26-429122.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [325 d](/filings/0001193125-26-060461.md) | [346](/filings/0000950170-25-060339.md) | [370](/filings/0000950170-25-098791.md) | [400](/filings/0001193125-25-249986.md) | [413 d](/filings/0001193125-26-060461.md) | [426](/filings/0001193125-26-174021.md) | [441](/filings/0001193125-26-314590.md) | [461](/filings/0001193125-26-429122.md) | [502 d](/filings/0001193125-26-060461.md) | [529](/filings/0001193125-26-174021.md) | [568](/filings/0001193125-26-314590.md) | [614](/filings/0001193125-26-429122.md) |
| Operating income | $m | [97.5 d](/filings/0001193125-26-060461.md) | [131](/filings/0000950170-25-060339.md) | [145](/filings/0000950170-25-098791.md) | [154](/filings/0001193125-25-249986.md) | [155 d](/filings/0001193125-26-060461.md) | [172](/filings/0001193125-26-174021.md) | [184](/filings/0001193125-26-314590.md) | [197](/filings/0001193125-26-429122.md) | [187 d](/filings/0001193125-26-060461.md) | [207](/filings/0001193125-26-174021.md) | [237](/filings/0001193125-26-314590.md) | [247](/filings/0001193125-26-429122.md) |
| Interest expense | $m | [57.2 d](/filings/0001193125-26-060461.md) | [65.6](/filings/0000950170-25-060339.md) | [71.0](/filings/0000950170-25-098791.md) | [76.9](/filings/0001193125-25-249986.md) | [77.0 d](/filings/0001193125-26-060461.md) | [80.5](/filings/0001193125-26-174021.md) | [82.8](/filings/0001193125-26-314590.md) | [87.0](/filings/0001193125-26-429122.md) | [89.0 d](/filings/0001193125-26-060461.md) | [94.0](/filings/0001193125-26-174021.md) | [97.8](/filings/0001193125-26-314590.md) | [104](/filings/0001193125-26-429122.md) |
| Income tax | $m | [6.9 d](/filings/0001193125-26-060461.md) | [16.2](/filings/0000950170-25-060339.md) | [19.7](/filings/0000950170-25-098791.md) | [12.1](/filings/0001193125-25-249986.md) | [13.7 d](/filings/0001193125-26-060461.md) | [18.1](/filings/0001193125-26-174021.md) | [24.9](/filings/0001193125-26-314590.md) | [29.9](/filings/0001193125-26-429122.md) | [19.8 d](/filings/0001193125-26-060461.md) | [21.8](/filings/0001193125-26-174021.md) | [35.0](/filings/0001193125-26-314590.md) | [35.5](/filings/0001193125-26-429122.md) |
| Net income | $m | [34.8 d](/filings/0001193125-26-060461.md) | [48.4](/filings/0000950170-25-060339.md) | [53.9](/filings/0000950170-25-098791.md) | [43.4](/filings/0001193125-25-249986.md) | [63.7 d](/filings/0001193125-26-060461.md) | [72.9](/filings/0001193125-26-174021.md) | [76.1](/filings/0001193125-26-314590.md) | [80.3](/filings/0001193125-26-429122.md) | [79.0 d](/filings/0001193125-26-060461.md) | [91.1](/filings/0001193125-26-174021.md) | [105](/filings/0001193125-26-314590.md) | [107](/filings/0001193125-26-429122.md) |
| Diluted EPS | $ per share | not reported | [1.64](/filings/0000950170-25-060339.md) | [1.93](/filings/0000950170-25-098791.md) | [1.57](/filings/0001193125-25-249986.md) | not reported | [2.69](/filings/0001193125-26-174021.md) | [2.86](/filings/0001193125-26-314590.md) | [3.03](/filings/0001193125-26-429122.md) | not reported | [3.46](/filings/0001193125-26-174021.md) | [4.00](/filings/0001193125-26-314590.md) | [4.06](/filings/0001193125-26-429122.md) |
| Basic EPS | $ per share | not reported | [1.72](/filings/0000950170-25-060339.md) | [2.00](/filings/0000950170-25-098791.md) | [1.64](/filings/0001193125-25-249986.md) | not reported | [2.84](/filings/0001193125-26-174021.md) | [3.01](/filings/0001193125-26-314590.md) | [3.22](/filings/0001193125-26-429122.md) | not reported | [3.66](/filings/0001193125-26-174021.md) | [4.22](/filings/0001193125-26-314590.md) | [4.31](/filings/0001193125-26-429122.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [54.4](/filings/0001193125-26-060461.md) | [76.5](/filings/0000950170-25-060339.md) | [60.1](/filings/0000950170-25-098791.md) | [67.5](/filings/0001193125-25-249986.md) | [73.9](/filings/0001193125-26-060461.md) | [55.5](/filings/0001193125-26-174021.md) | [55.6](/filings/0001193125-26-314590.md) | [53.6](/filings/0001193125-26-429122.md) | [71.7](/filings/0001193125-26-429122.md) | [96.1](/filings/0001193125-26-174021.md) | [122](/filings/0001193125-26-314590.md) | [106](/filings/0001193125-26-429122.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $m | [4,586](/filings/0000950170-25-022244.md) | [4,637](/filings/0000950170-25-060339.md) | [4,817](/filings/0000950170-25-098791.md) | [4,976](/filings/0001193125-25-249986.md) | [5,266](/filings/0001193125-26-060461.md) | [5,457](/filings/0001193125-26-174021.md) | [5,725](/filings/0001193125-26-314590.md) | [5,962](/filings/0001193125-26-429122.md) | [6,468](/filings/0001193125-26-429122.md) | [6,877](/filings/0001193125-26-174021.md) | [7,222](/filings/0001193125-26-314590.md) | [7,696](/filings/0001193125-26-429122.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total liabilities | $m | [3,345](/filings/0000950170-25-022244.md) | [3,486](/filings/0000950170-25-060339.md) | [3,670](/filings/0000950170-25-098791.md) | [3,797](/filings/0001193125-25-249986.md) | [4,069](/filings/0001193125-26-060461.md) | [4,261](/filings/0001193125-26-174021.md) | [4,496](/filings/0001193125-26-314590.md) | [4,679](/filings/0001193125-26-429122.md) | [5,132](/filings/0001193125-26-429122.md) | [5,475](/filings/0001193125-26-174021.md) | [5,725](/filings/0001193125-26-314590.md) | [6,127](/filings/0001193125-26-429122.md) |
| Long-term debt | $m | [2,944](/filings/0000950170-25-022244.md) | [3,041](/filings/0000950170-25-060339.md) | [3,194](/filings/0000950170-25-098791.md) | [3,294](/filings/0001193125-25-249986.md) | [3,563](/filings/0001193125-26-060461.md) | [3,757](/filings/0001193125-26-174021.md) | [3,964](/filings/0001193125-26-314590.md) | [4,106](/filings/0001193125-26-429122.md) | [4,498](/filings/0001193125-26-429122.md) | [4,833](/filings/0001193125-26-174021.md) | [5,014](/filings/0001193125-26-314590.md) | [5,377](/filings/0001193125-26-429122.md) |
| Shareholders' equity | $m | [1,240](/filings/0000950170-25-022244.md) | [1,150](/filings/0000950170-25-060339.md) | [1,148](/filings/0000950170-25-098791.md) | [1,179](/filings/0001193125-25-249986.md) | [1,197](/filings/0001193125-26-060461.md) | [1,197](/filings/0001193125-26-174021.md) | [1,229](/filings/0001193125-26-314590.md) | [1,284](/filings/0001193125-26-429122.md) | [1,337](/filings/0001193125-26-429122.md) | [1,402](/filings/0001193125-26-174021.md) | [1,497](/filings/0001193125-26-314590.md) | [1,569](/filings/0001193125-26-429122.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: not reported
- Total assets: us-gaap:Assets
- Current liabilities: not reported
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [314 d](/filings/0001193125-26-060461.md) | [349](/filings/0000950170-25-060339.md) | [361 d](/filings/0000950170-25-098791.md) | [399 d](/filings/0001193125-25-249986.md) | [431 d](/filings/0001193125-26-060461.md) | [391](/filings/0001193125-26-174021.md) | [447 d](/filings/0001193125-26-314590.md) | [482 d](/filings/0001193125-26-429122.md) | [499 d](/filings/0001193125-26-060461.md) | [475](/filings/0001193125-26-174021.md) | [544 d](/filings/0001193125-26-314590.md) | [536 d](/filings/0001193125-26-429122.md) |
| Capital expenditure | $m | [11.8 d](/filings/0001193125-26-060461.md) | [11.2](/filings/0000950170-25-060339.md) | [11.1 d](/filings/0000950170-25-098791.md) | [10.9 d](/filings/0001193125-25-249986.md) | [10.2 d](/filings/0001193125-26-060461.md) | [12.9](/filings/0001193125-26-174021.md) | [11.2 d](/filings/0001193125-26-314590.md) | [11.3 d](/filings/0001193125-26-429122.md) | [11.7 d](/filings/0001193125-26-060461.md) | [10.8](/filings/0001193125-26-174021.md) | [12.6 d](/filings/0001193125-26-314590.md) | [11.6 d](/filings/0001193125-26-429122.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [66.8 d](/filings/0001193125-26-060461.md) | [151](/filings/0000950170-25-060339.md) | [63.4 d](/filings/0000950170-25-098791.md) | [23.3 d](/filings/0001193125-25-249986.md) | [51.2 d](/filings/0001193125-26-060461.md) | [85.5](/filings/0001193125-26-174021.md) | [55.3 d](/filings/0001193125-26-314590.md) | [38.4 d](/filings/0001193125-26-429122.md) | [35.3 d](/filings/0001193125-26-060461.md) | [39.6](/filings/0001193125-26-174021.md) | [19.8 d](/filings/0001193125-26-314590.md) | [46.3 d](/filings/0001193125-26-429122.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.7](/filings/0000950170-24-047610.md) | [32.2](/filings/0000950170-24-086053.md) | [31.9](/filings/0000950170-24-116660.md) | [29.5](/filings/0000950170-25-060339.md) | [27.9](/filings/0000950170-25-098791.md) | [27.7](/filings/0001193125-25-249986.md) | [27.1](/filings/0001193125-26-174021.md) | [26.6](/filings/0001193125-26-314590.md) | [26.5](/filings/0001193125-26-429122.md) | [26.3](/filings/0001193125-26-174021.md) | [26.3](/filings/0001193125-26-314590.md) | [26.4](/filings/0001193125-26-429122.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,460,078 at 2026-10-19, from the cover of the [10-Q filed 2026-10-22](/filings/0001193125-26-429122.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.